SURGICAL MANAGEMENT OF Abnormal tone

James Botros, MD Pediatric Neurosurgery

THE UNIVERSITY OF NEW MEXICO.

DISCLOSURES

• No financial disclosures to report

OBJECTIVES

- Identify candidates for surgical management of increased tone
- Describe surgical options for appropriate candidates
- Identify risks, benefits, and alternatives of surgery

ABNORMAL TONE

- Spasticity
- Dystonia
- Chorea
- Athetosis
- Rigidity
- Atonia

INCIDENCE

- Cerebral palsy
 - 1 in 3000 live births
- Stroke
- Head injury
- Brain tumor

TABLE. Estimated prevalence and lifetime economic costs* for mental retardation, cerebral palsy, hearing loss, and vision impairment, by cost category — United States, 2003

Developmental disability	Rate ⁺	Direct medical costs⁵ (millions)	Direct nonmedical costs [¶] (millions)	Indirect costs** (millions)	Total costs (millions)	Average costs per person
Mental retardation	12.0	\$7,061	\$5,249	\$38,927	\$51,237	\$1,014,000
Cerebral palsy	3.0	1,175	1,054	9,241	11,470	921,000
Hearing loss	1.2	132	640	1,330	2,102	417,000
Vision impairment	1.1	159	409	1,915	2,484	566,000

Present value estimates, in 2003 dollars, of lifetime costs for persons born in 2000, based on a 3% discount rate.

¹ Per 1,000 children aged 5–10 years, on the basis of Metropolitan Atlanta Developmental Disabilities Surveillance Program data for 1991–1994. Includes physician visits, prescription medications, hospital inpatient stays, assistive devices, therapy and rehabilitation (for persons aged <18 years), and long-term care (for persons aged 18–76 years), adjusted for age-specific survival.

long-term care (for persons aged 18–76 years), adjusted for age-specific survival. Includes costs of home and vehicle modifications for persons aged ≤76 years and costs of special education for persons aged 3–17 years.

** Includes productivity losses from increased morbidity (i.e., inability to work or limitation in the amount or type of work performed) and premature mortality for persons aged <35 years with mental retardation, aged <25 years with cerebral palsy, and aged <17 years with hearing loss and vision impairment.</p>

- Hereditary
- Idiopathic



MULTIDISCIPLINARY MANAGEMENT

- Pediatrician
- Neurologist
- Neurosurgeon
- Physiatrist
- Physical therapist
- Occupational therapist
- Speech therapist

SPASTICITY

- "resistance to externally imposed movement that increases with increasing speed of stretch and varies with the direction of joint movement, and/or resistance to externally imposed movement that rises rapidly above a threshold speed or joint angle"
- Varies with movement, alertness, pain, anxiety
- Isokinetic, not hyperkinetic
- Most common type of abnormal tone
- Affects 60% of cerebral palsy patients; stroke, head injury, idiopathic
- Classified by affected limbs spastic diplegia, spastic hemiplegia, spastic quadriplegia, spastic monoplegia

SPASTICITY



MANAGEMENT

- Goals of treatment
 - Improve function
 - Facilitate care
 - Reduce contractures
 - Reduce pain
- Oral medications
 - Baclofen (GABA agonist), diazepam, tizanidine
- Botox injections
- Therapy
- Surgery

EVALUATION



GMFCS Level I

Children walk indoors and outdoors and climb stairs without limitation. Children perform gross motor skills including running and jumping, but speed, balance and coordination are impaired.

GMFCS Level II

Children walk indoors and outdoors and climb stairs holding onto a railing but experience limitations walking on uneven surfaces and inclines and walking in crowds or confined spaces.

GMFCS Level III

Children walk indoors and outdoors on a level surface with an assistive mobility device. Children may climb stairs holding onto a railing. Children may propel a wheelchair manually or are transported when traveling for long distances or outdoors on uneven terrain.

GMFCS Level IV

Children may continue to walk for short distances on a walker or rely more on wheeled mobility at home and school and in the community.

GMFCS Level V

Physical impairment restricts voluntary control of movement and the ability to maintain antigravity head and trunk postures. All areas of motor function are limited. Children have no means of independent mobility and are transported.

Grade	Description
0	no increase in muscle tone
1	slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or exten- sion
1+	slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM
2	more marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
3	considerable increase in muscle tone, passive movement difficult
4	affected part(s) rigid in flexion or extension











SELECTIVE DORSAL RHIZOTOMY

	Mirror Graphic
lon organ Muscle fiber Muscle spindle	



SELECTIVE DORSAL RHIZOTOMY



INDICATIONS/ CONTRAINDICATIONS

TABLE 227-1 Indications for Selective Dorsel Rhizotomy for Spastic Corebral Polay

Diagnosis—spastic diplegia or quadriplegia Age—2 to 40 years History of premature birth or neonatal asphyxia Emerging locomotive functions Potential for significant postoperative functional gain

TABLE 227-2 Contraindications to Selective Dorsal Rhizotomy for Spastic Cerebral Palsy

CP associated with intrauterine encephalitis

Mixed CP with predominant dystonia or ataxia

CP caused by a widespread neuronal migration disorder

Severe head injury and hypoxic encephalopathy, such as after drowning

Familial spastic paraplegia and other progressive neurological disorders

Severe basal ganglia damage in children younger than 5 years Severe thoracolumbar scoliosis

Severe lumbar lordosia

Multiple previous muscle and tendon releases

Profound motor impairment with no head control

Psychiatric disorders in adults

Lack of commitment to carry out postoperative therapy



- Bleeding
- Infection
- CSF leak
- Spinal deformity

https://youtu.be/IcFcDgNEwUE



• <u>https://youtu.be/wA7TKfI2WeM</u>



INTRATHECAL BACLOFEN PUMP

- Intrathecal catheter with subcutaneous pump/reservoir
- 20cc or 40cc reservoir
- Suitable for pts >10kg
- Catheter tip can be cervical or thoracic
- Can titrate dose to effect

IT baclofen – 396ug/day = CSF level 400ng/ml PO baclofen - 60mg/day = CSF level 12ng/ml





- Mechanical failure
- Catheter fracture/migration
- Infection
- CSF leak
- Need for lifelong follow up
- Risk of withdrawal or overdose

<u>https://youtu.be/JdwCbH77MYg</u>



SUMMARY

Table 76.3 Treatments for Spasticity

Method	Age (y)	Diagnosis	Characteristics.	Expected results	Follow-up-care	Outcome	Side effects, risk
Oral medications	Any age, most often 2 to 5	Spastic quadriplegia. traumatic brain injury	Diffuse spasticity	Mild decrease in spasticity in arms and legs	PT. OT as needed	SPRs or IT8 often needed later	Drowsiness
Botox injections	Any age, less often older than 10	Spastic diplegia, spastic quadriplegia	tsolated spasticity; too young for ITB, SPRs	Decrease in spasticity in injected muscle(s) for 2 to 4 months	PT, OT to increase range of motion and to increase strength	Improved gait. sometimes improved arm function	None with usual dones
Rhizotomy (SPRs)	4 to 8 (most common), vare after 16	Spastic diplegia or quad- riplegia, capable of ADLs	Good leg strength, no se- vere contractures, motiva- tion for PT	Marked, permanent, nonadjustable decrease in spasticity	Estensive PT, OT	improved walking, improved ADLs, de- crease in orthopedic operations	Infection, 2%. wound, 1%; CSF leak, 3%
	Older than age 3, be- fore multiple contrac- tions	Spantic diplegia or quad- riplegia, not capable of ADEs	Severe leg spasticity inter- fering with care		Minimal	Easier care	Infection, 2%; wound, 1%; CSF leak, 3%
Backolen (ITB)	Older than age 3, hig enough to insert pump	Spastic quadriplegia. spasticity in legs greater than or equal to spasticity in arms, copuble of ADLs	Severe spatilicity, positive response to test dose, spas- ticity limiting function	Adjustable decrease in spasticity	Frequency of PT, OT depends on goals	Improved walking, improved ADEs, im- proved speech, de- crease in orthopedic operations, easier case	Infection, 5 to 10%; wound, 5 to 10%; C3F leak, 5 to 10%
		Spastic quadriplegia, nor capable of ADLs	Spanticity interfering with care		Minimal PT	Easier care	
		Posttraumatic brain injury	Severe spaticity in arms or legs, usually more than 1 year after injury		PT, OT for range of motion		

Abbreviations: ADLs, activities of daily living: CSF, cerebral spinal fluid: ITB, intrathecal baclofen: OT, occupational therapy; PT, physical therapy; SPRs, selective posterior rhizotomies.

DYSTONIA

- "a movement disorder in which involuntary sustained or intermittent muscle contractions cause twisting and repetitive movements, abnormal postures, or both"
- Hyperkinetic
- Focal, segmental, hemidystonia, generalized
- Primary (hereditary DYT genes) vs secondary (CP, stroke, head injury, tumor)
- Affects 15-25% of cerebral palsy patients

DYSTONIA



MANAGEMENT

- Goals of treatment
 - Improve function
 - Facilitate care
 - Reduce contractures
 - Reduce pain
- Oral medications
 - Baclofen, trihexyphenidyl (Artane), dopa
- Botox injections
- Surgery

INTRATHECAL BACLOFEN PUMP

- Intrathecal catheter with subcutaneous pump/reservoir
- 20cc or 40cc reservoir
- Suitable for pts >10kg





DEEP BRAIN STIMULATION

- Most experience is with adult movement disorders (Parkinson's disease, essential tremor)
- Has been used in pediatric dystonia
- Appears more effective for **primary** dystonia
- Typically target is globus pallidus interna
- Modulates the cortical-basal gangliacortical loop

Deep brain stimulation (DBS)

The DBS system is used to help control tremors and chronic movement disorders, like Parkinson's disease. Tiny electrodes are connected via a subcutaneous wire to a neurostimulator implanted under the skin near the clavicle.



Figure 4 Components of the Deep Brain Stimulation system

<u>https://youtu.be/jtyCTk3OBpQ</u>



ATHETOSIS/CHOREA

- Athetosis = "slow, distal, wormlike, writing movements of the extremities, with fanning or hyperextension of the digits"
- Chorea = "a state of excessive, spontaneous movements, irregularly timed, nonrepetitive, abrupt in character, involuntary, rapid, brief, unsustained, dancelike movements"
- Do not respond well to surgical management important to distinguish from dystonia

<u>https://youtu.be/XCzdUiSo8Y8</u>



UNM TONE CLINIC

- First Friday of every month
- Staff
 - James Botros, MD and Barbara Bell, NP, Neurosurgery
 - John Phillips, MD, Neurology
 - Denise Taylor, MD, PM&R
 - Angela Kouri, PT
 - Catherine Burke, PT
- Send referrals!

REFERENCES

- Peacock WJ, Arens LJ, Berman B. Cerebral palsy spasticity. Selective posterior rhizotomy. Pediatr Neurosci 1987; 13: 61-66.
- Sanger TD, Delgado MR, Gaebler-Spira D, Hallet M, Mink JW. Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111: e89-e97.
- Sanger TD. Pathophysiology of pediatric movement disorders. J Child Neurol 2003; 18 Suppl 1: S9-S24.
- Hoon AH, Belsito KM, Nagae-Poetscher LM. Neuroimaging in spasticity and movement disorders. J Child Neurol 2003; 18 Suppl 1: S25-S39.
- Edgar TS. Oral pharmacotherapy of childhood movement disorders. J Child Neurol 2003; 18 Suppl 1: S40-S49.
- Boyd RN, Hays RM. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 2001; 8 Suppl 5: 1-20.
- Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270: 2475-2477.
- Albright AL, Ferson SS, Carlos S. Occult hydrocephalus in children with cerebral palsy. Neurosurgery 2005; 56: 93-96.
- Zuckerbraun NS, Ferson SS, Albright AL, Vogeley E. Intrathecal baclofen withdrawal: emergent recognition and management. Pediatr Emerg Care 2004; 20: 759-764.
- Albright AL, Ferson SS. Intraventricular baclofen for dystonia: techniques and outcomes. Clinical article. J Neurosurg Pediatr 2009; 3: 11-14.
- Coubes P, Cif L, El Fertit H et al. Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia: long-term results. J Neurosurg 2004; 101: 189-194.